These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 12173783)

  • 21. Fat, sugar and drugs on the French Riviera.
    Lands L
    GMHC Treat Issues; 1999 Mar; 13(3):9-11. PubMed ID: 11366205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toxicity of antiretroviral therapy and implications for drug development.
    Carr A
    Nat Rev Drug Discov; 2003 Aug; 2(8):624-34. PubMed ID: 12904812
    [No Abstract]   [Full Text] [Related]  

  • 23. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
    Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR
    J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protease inhibitor-sparing simplified maintenance therapy: a need for perspective.
    Bucher HC; Young J; Battegay M
    J Antimicrob Chemother; 2004 Aug; 54(2):303-5. PubMed ID: 15269200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human immunodeficiency virus-associated rheumatic disorders in the HAART era.
    Marquez J; Restrepo CS; Candia L; Berman A; Espinoza LR
    J Rheumatol; 2004 Apr; 31(4):741-6. PubMed ID: 15088301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Problems in the management of HIV infection in clinical practice. Patients still on dual therapy 8 years after the introduction of HAART].
    Manfredi R
    Recenti Prog Med; 2003 Nov; 94(11):506-7. PubMed ID: 14679919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteopenia in HIV infection.
    Carr A
    AIDS Clin Care; 2001 Aug; 13(8):71-3, 78. PubMed ID: 11547460
    [No Abstract]   [Full Text] [Related]  

  • 30. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.
    Maggiolo F; Ripamonti D; Torti C; Arici C; Antinori A; Quiros-Roldan E; Minoli L; Sighinolfi L; Nasta P; Suter F;
    Antivir Ther; 2006; 11(7):923-9. PubMed ID: 17302255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. "Solving the puzzle" of current HAART: what key strategic trials are needed?
    Carosi G; Torti C
    New Microbiol; 2004 Apr; 27(2 Suppl 1):127-30. PubMed ID: 15646075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir.
    Benesic A; Zilly M; Kluge F; Weissbrich B; Winzer R; Klinker H; Langmann P
    Infection; 2004 Aug; 32(4):229-33. PubMed ID: 15293079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum leptin and bone metabolism in HIV patients treated with highly active antiretroviral therapy.
    Madeddu G; Spanu A; Chessa F; Calia GM; Lovigu C; Mannazzu M; Falchi A; Sanna D; Mura MS; Madeddu G
    Q J Nucl Med Mol Imaging; 2009 Jun; 53(3):290-301. PubMed ID: 18596668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors.
    Introcaso CE; Hines JM; Kovarik CL
    J Am Acad Dermatol; 2010 Oct; 63(4):549-61; quiz 561-2. PubMed ID: 20846563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection.
    Paik IJ; Kotler DP
    Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):469-78. PubMed ID: 21663840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Etiology and pharmacologic management of noninfectious diarrhea in HIV-infected individuals in the highly active antiretroviral therapy era.
    MacArthur RD; DuPont HL
    Clin Infect Dis; 2012 Sep; 55(6):860-7. PubMed ID: 22700829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Multifactorial relations between HIV, HAART and bone metabolism].
    Borderi M
    Infez Med; 2006 Sep; 14(3):117-24. PubMed ID: 17127825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HAART-related nephropathies in HIV-infected patients.
    Daugas E; Rougier JP; Hill G
    Kidney Int; 2005 Feb; 67(2):393-403. PubMed ID: 15673287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone disease in the setting of HIV infection: update and review of the literature.
    Castronuovo D; Cacopardo B; Pinzone MR; Di Rosa M; Martellotta F; Schioppa O; Moreno S; Nunnari G
    Eur Rev Med Pharmacol Sci; 2013 Sep; 17(18):2413-9. PubMed ID: 24089217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.